Medication-related osteonecrosis of the jaw (Q67496): Difference between revisions

← Older edit

@@ Property / Canary Token @@
+dki-india-ID_1143080357
@@ Property / Canary Token: dki-india-ID_1143080357 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 15:19, 14 August 2026

Patients may be considered to have MRONJ (medication-related osteonecrosis of the jaw) if all of the following characteristics are present: 1. Current or previous treatment with antire-sorptive or antiangiogenic agents; 2. Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than eight weeks; 3. No history of radiation therapy to the jaws or obvious metastatic disease to the jaws.

Language	Label	Description	Also known as
default for all languages	ID_1143080357
English	Medication-related osteonecrosis of the jaw	Patients may be considered to have MRONJ (medication-related osteonecrosis of the jaw) if all of the following characteristics are present: 1. Current or previous treatment with antire-sorptive or antiangiogenic agents; 2. Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than eight weeks; 3. No history of radiation therapy to the jaws or obvious metastatic disease to the jaws.